Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease
- PMID: 16466929
- DOI: 10.1016/j.nbd.2005.11.002
Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease
Abstract
Mild cognitive impairment (MCI) is generally referred to the transitional zone between normal cognitive function and early dementia or clinically probable Alzheimer's disease (AD). Oxidative stress plays a significant role in AD and is increased in the superior/middle temporal gyri of MCI subjects. Because AD involves hippocampal-resident memory dysfunction, we determined protein oxidation and identified the oxidized proteins in the hippocampi of MCI subjects. We found that protein oxidation is significantly increased in the hippocampi of MCI subjects when compared to age- and sex-matched controls. By using redox proteomics, we determined the oxidatively modified proteins in MCI hippocampus to be alpha-enolase (ENO1), glutamine synthetase (GLUL), pyruvate kinase M2 (PKM2) and peptidyl-prolyl cis/trans isomerase 1 (PIN1). The interacteome of these proteins revealed that these proteins functionally interact with SRC, hypoxia-inducible factor 1, plasminogen (PLG), MYC, tissue plasminogen activator (PLAT) and BCL2L1. Moreover, the interacteome indicates the functional involvement of energy metabolism, synaptic plasticity and mitogenesis/proliferation. Therefore, oxidative inactivation of ENO1, GLUL and PIN1 may alter these cellular processes and lead to the development of AD from MCI. We conclude that protein oxidation plays a significant role in the development of AD from MCI and that the oxidative inactivation of ENO1, GLUL, PKM2 and PIN1 is involved in the progression of AD from MCI. The current study provides a framework for future studies on the development of AD from MCI relevant to oxidative stress.
Similar articles
-
Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis.Neurobiol Aging. 2006 Jul;27(7):918-25. doi: 10.1016/j.neurobiolaging.2005.05.005. Epub 2005 Jun 13. Neurobiol Aging. 2006. PMID: 15950321
-
Redox proteomics identification of specifically carbonylated proteins in the hippocampi of triple transgenic Alzheimer's disease mice at its earliest pathological stage.J Proteomics. 2015 Jun 18;123:101-13. doi: 10.1016/j.jprot.2015.04.005. Epub 2015 Apr 15. J Proteomics. 2015. PMID: 25890254
-
Pin1 in Alzheimer's disease.J Neurochem. 2006 Sep;98(6):1697-706. doi: 10.1111/j.1471-4159.2006.03995.x. J Neurochem. 2006. PMID: 16945100 Review.
-
Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD.Neurobiol Aging. 2006 Nov;27(11):1564-76. doi: 10.1016/j.neurobiolaging.2005.09.021. Epub 2005 Nov 4. Neurobiol Aging. 2006. PMID: 16271804
-
Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.Acta Neuropathol. 2009 Jul;118(1):131-50. doi: 10.1007/s00401-009-0517-0. Epub 2009 Mar 14. Acta Neuropathol. 2009. PMID: 19288120 Free PMC article. Review.
Cited by
-
Regional expression of key cell cycle proteins in brain from subjects with amnestic mild cognitive impairment.Neurochem Res. 2007 Apr-May;32(4-5):655-62. doi: 10.1007/s11064-006-9123-x. Epub 2006 Sep 28. Neurochem Res. 2007. PMID: 17006763
-
Nitric oxide contributes to protein homeostasis by S-nitrosylations of the chaperone HSPA8 and the ubiquitin ligase UBE2D.Redox Biol. 2019 Jan;20:217-235. doi: 10.1016/j.redox.2018.10.002. Epub 2018 Oct 16. Redox Biol. 2019. PMID: 30368041 Free PMC article.
-
Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases.Molecules. 2018 Dec 13;23(12):3305. doi: 10.3390/molecules23123305. Molecules. 2018. PMID: 30551603 Free PMC article. Review.
-
Astrocytes in human central nervous system diseases: a frontier for new therapies.Signal Transduct Target Ther. 2023 Oct 13;8(1):396. doi: 10.1038/s41392-023-01628-9. Signal Transduct Target Ther. 2023. PMID: 37828019 Free PMC article. Review.
-
Emerging Mechanisms and Targeted Therapy of Ferroptosis in Neurological Diseases and Neuro-oncology.Int J Biol Sci. 2022 Jun 27;18(10):4260-4274. doi: 10.7150/ijbs.72251. eCollection 2022. Int J Biol Sci. 2022. PMID: 35844784 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous